James F Cleary
Affiliation: University of Wisconsin
- The pharmacologic management of cancer painJames F Cleary
Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792, USA
J Palliat Med 10:1369-94. 2007..Much of the work obtained from the study of cancer patients is applicable to the non cancer populations, as is work performed in non cancer patients with neuropathic pain...
- Caregivers' participation in the oncology clinic visit mediates the relationship between their information competence and their need fulfillment and clinic visit satisfactionLori L DuBenske
University of Wisconsin Madison, Center for Health Enhancement Systems Studies, Madison, WI 53726, USA
Patient Educ Couns 81:S94-9. 2010..This study examines the mediating role caregiver's clinic visit involvement has on the relationships between caregiver's information competence and their need fulfillment and clinic visit satisfaction...
- Creating a bond between caregivers online: effect on caregivers' coping strategiesKang Namkoong
School of Journalism and Mass Communication, and Center for Health Enhancement Systems Studies, University of Wisconsin, Madison, Wisconsin 53706, USA
J Health Commun 17:125-40. 2012..Findings suggest that perceived bonding has positive effects on caregivers' appraisal and problem-focused coping strategies, and it mediates the effect of ICCS on the coping strategies 6 months after the intervention has begun...
- Development and implementation of a clinician reporting system for advanced stage cancer: initial lessons learnedLori L DuBenske
Center for Health Enhancement Systems Studies, University of Wisconsin, Madison, Wisconsin, USA
J Am Med Inform Assoc 15:679-86. 2008..This study reports initial findings from implementation of the Clinician Report (CR)-a patient and caregiver status report tool accessible by the oncology clinic team...
- Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancerPaul R Hutson
School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705 2222, USA
Clin Cancer Res 11:8722-7. 2005..Clinical trials combining tamoxifen with letrozole or anastrazole have shown minor pharmacokinetic drug interactions. We did an open-label crossover clinical trial of the effect of exemestane on tamoxifen pharmacokinetics...
- Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancerRichard R Love
Department of Medicine, University of Wisconsin, 610 Walnut Street, 256 Warf Office Building, Madison, WI 53726, USA
Clin Cancer Res 11:1500-3. 2005..To evaluate the endocrine effects of the combination of exemestane and tamoxifen, we studied 33 postmenopausal women disease-free following primary treatments for breast cancer who were taking tamoxifen for at least 3 months...
- Web-based cancer communication and decision making systems: connecting patients, caregivers, and clinicians for improved health outcomesLori L DuBenske
School of Medicine and Public Health, Department of Psychiatry, University of Wisconsin Madison, USA
Med Decis Making 30:732-44. 2010..Implementation strategies should address timing, personnel, and environmental factors to facilitate continued use and benefit from IHCS...
- Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignanciesSteven Attia
University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
Cancer Chemother Pharmacol 64:45-51. 2009..To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine...
- Cancer information sources used by patients to inform and influence treatment decisionsMatthew C Walsh
Paul P Carbone Comprehensive Cancer Center, and Department of Population Health Sciences, University of Wisconsin Madison, Madison, Wisconsin, USA
J Health Commun 15:445-63. 2010..These findings provide a deeper understanding of the information needs of cancer patients and have implications for dissemination strategies that can minimize disparities in access to cancer information...
- Opioid analgesics for pain control: wisconsin physicians' knowledge, beliefs, attitudes, and prescribing practicesMarla Z Wolfert
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin WI 53792, USA
Pain Med 11:425-34. 2010..Although their role in the management of chronic pain not related to cancer is controversial, there is increasing evidence for their benefit in certain patient populations...
- Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experienceAnne M Traynor
Section of Hematology and Medical Oncology, University of Wisconsin, Paul P Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
Head Neck 32:599-606. 2010....
- Materials to prepare hospice families for dying in the homeKaren A Kehl
School of Nursing, University of Wisconsin, Madison, Wisconsin 53792 2455, USA
J Palliat Med 11:969-72. 2008..1%), surge of energy (11.8%) and mandibular breathing (5.9%). Hospice staff should know the content of the materials offered by their agency so they can verbally address the gaps between the written materials and family needs...
- Caregivers' differing needs across key experiences of the advanced cancer disease trajectoryLori L DuBenske
Center for Health Enhancement Systems Studies, University of Wisconsin, Madison, Wisconsin 53706, USA
Palliat Support Care 6:265-72. 2008..This study examines a variety of particular needs across a number of more discrete illness-related transition experiences specifically in the advanced cancer disease trajectory...
- Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridolJames P Thomas
University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, 600 Highland Ave, Madison, WI 53792, USA
Cancer Chemother Pharmacol 50:465-72. 2002..The manageable gastrointestinal toxicity, early signs of clinical activity and lack of hematologic toxicity make further exploration in combination trials warranted...
- Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapyNoelle K Loconte
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Ave, CSC K4 548, Madison, WI 53792, USA
Cancer Chemother Pharmacol 65:775-80. 2010..The goal of this study was to identify clinical and nonclinical factors which were associated with the development of DLT in phase I studies...
- Integrating palliative care into head and neck oncologyJames F Cleary
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
Int J Radiat Oncol Biol Phys 69:S83-5. 2007
- Ensuring patient access to essential medicines while minimizing harmful use: a revised World Health Organization tool to improve national drug control policyAaron M Gilson
University of Wisconsin Carbone Cancer Center, 1300 University Avenue, Madison, WI 53706, USA
J Pain Palliat Care Pharmacother 25:246-51. 2011..It is hoped that representatives of governments and medical institutions, as well as health care professionals, will commonly and effectively use the revised WHO guidelines as a policy change tool...
- Predictors of hospice utilization among acute stroke patients who died within thirty daysAmanda E duPreez
Center for Women s Health Research, University of Wisconsin School of Medicine and Public Health and Meriter Hospital, Madison, Wisconsin 53726, USA
J Palliat Med 11:1249-57. 2008..The highest mortality among stroke patients occurs within the first 30 days; however, we know little about the hospice enrollment decision for this population during this critical time frame...
- Patient/Caregiver influences for declining participation in supportive oncology trialsMary K Buss
Division of Hematology Oncology and Palliative Care Consultation Service, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Rose 144, Boston, MA 02215, USA
J Support Oncol 6:168-74. 2008..This information was specific to supportive care trials; it may help researchers plan recruitment strategies and enrollment targets...
- Incident painJames F Cleary
Palliat Med 19:1-2. 2005
- Consensus statement: Palliative and supportive care in advanced heart failureSarah J Goodlin
Institute for Health Care Delivery and Research, Intermountain Health Care, Salt Lake City, Utah 84111, USA
J Card Fail 10:200-9. 2004....
- A day in the life of European palliative careJames F Cleary
Palliat Med 19:442-3. 2005